Rådgivning
från idé till
investering

Efter över 3 000 kundmöten och ett 50-tal djupintervjuer är bilden tydlig – många private banking-kunder efterfrågar något nytt.

Vi öppnar dörrarna – och välkomnar nya kunder löpande.
Anmäl ditt intresse och få förtur via vår intresselista när nya platser blir tillgängliga.

Senaste artiklar

Senaste transaktionerna från ABG Sundal Collier

2025

volue infrastructure 02072025

M&A

Undisclosed

Norway

IT

ABG Sundal Collier acted as exclusive financial adviser to FSN Capital Partners in relation to FSN Capital VI’s acquisition of Volue Infrastructure

On 2 July 2025, FSN Capital VI announced that it had entered into a definitive agreement to acquire Volue Infrastructure, a carve-out of Volue’s infrastructure division and a leading Nordic provider of mission-critical niche infrastructure software for the water & communities and heavy-construction markets.

Volue Infrastructure’s modular, cutting-edge software tools are at the forefront of infrastructure digitalisation, and its offering is anchored in the long-established Gemini product family. Its Water & Communities suite covers the entire water value chain – combining network documentation, hydraulic simulation, real-time leak detection, asset management, billing and citizen engagement tools – to help municipal and regional utilities reduce water loss, meet regulatory targets and enhance customer service. The Heavy Construction suite connects 3D digital design models to on-site execution through modules for terrain modelling, quantity surveying, progress tracking and energy-use optimisation, enabling contractors and authorities to deliver projects faster, more accurately and with a lower carbon footprint.

ABG Sundal Collier acted as exclusive financial adviser to FSN Capital.

2025

Flat Capital

ECM

SEK 600m

Sweden

Financials

ABG Sundal Collier acts as Sole Global Coordinator in the SEK 600 million share issue in Flat Capital

On 2 June 2025, Flat Capital (“Flat Capital” or the “Company”) announced a SEK 300 million rights issue along with a potential overallotment issue of up to SEK 130 million. On 1 July 2025, the Company announced the final outcome of the rights issue, which was oversubscribed by approximately 260%. Due to the strong demand, Flat Capital decided to increase the overallotment issue to SEK 300 million, resulting in total gross proceeds of SEK 600 million.

Approximately 76% of the rights issue was secured through subscription commitments from existing shareholders Dusco AB, Altocumulus Investment AB, Frankenius Noterat AB, Cicero Fonder, and Karolina Tham von Heidenstam as well as from new investors including Iliakos AB (wholly owned by Mathias Kamprad), Tuesday Invest AB (wholly owned by Karl-Johan Persson), William Olsson, and Sofia and Märta Schörling.

The purpose of the rights issue was to further strengthen Flat Capital’s cash position to be able to quickly act on investment opportunities in the portfolio and network. ABG Sundal Collier acted as Sole Global Coordinator in the share issue

2025

oncoinvent 01072025 02

ECM

NOK 130m

Norway

Health care

ABG Sundal Collier is acting as exclusive financial advisor to Oncoinvent in connection with the merger with BerGenBio and as joint lead manager and joint bookrunner in connection with the NOK 130m fully underwritten rights issue

On 30 June 2025, BerGenBio ASA (“BerGenBio”) and Oncoinvent ASA (“Oncoinvent”) announced that they have entered into a merger agreement to combine the two companies through a statutory merger, where BerGenBio will be the acquiring entity. Following the merger, the combined company shall carry out a NOK 130m fully underwritten rights issue.

ABG Sundal Collier acted as exclusive financial advisor to Oncoinvent in connection with the merger and is acting as joint lead manager and joint bookrunner in connection with the NOK 130m fully underwritten rights issue.

The merger will add approximately NOK 45 million in cash to fund Oncoinvent’s clinical development plan, and together with the proceeds from the rights issue, fund the company through several milestones. Moreover, the combination will substantially broaden the shareholder base, improving liquidity in the share and enable an uplisting from Euronext Growth Oslo, subject to approval by the Oslo Stock Exchange.

The merger is supported by BerGenBio’s largest shareholder Meteva AS and Oncoinvent’s largest shareholders, Hadean Ventures and Linc AB, all of whom have entered into voting undertakings to vote in favour of the merger and lock-up commitments for a period of six months following this announcement. The merger is expected to be completed in around mid September and the rights issue is expected to be completed during October 2025.

2025

oncoinvent 01072025

M&A

Undisclosed

Norway

Health care

ABG Sundal Collier is acting as exclusive financial advisor to Oncoinvent in connection with the merger with BerGenBio and as joint lead manager and joint bookrunner in connection with the NOK 130m fully underwritten rights issue

On 30 June 2025, BerGenBio ASA (“BerGenBio”) and Oncoinvent ASA (“Oncoinvent”) announced that they have entered into a merger agreement to combine the two companies through a statutory merger, where BerGenBio will be the acquiring entity. Following the merger, the combined company shall carry out a NOK 130m fully underwritten rights issue.

ABG Sundal Collier acted as exclusive financial advisor to Oncoinvent in connection with the merger and is acting as joint lead manager and joint bookrunner in connection with the NOK 130m fully underwritten rights issue.

The merger will add approximately NOK 45 million in cash to fund Oncoinvent’s clinical development plan, and together with the proceeds from the rights issue, fund the company through several milestones. Moreover, the combination will substantially broaden the shareholder base, improving liquidity in the share and enable an uplisting from Euronext Growth Oslo, subject to approval by the Oslo Stock Exchange.

The merger is supported by BerGenBio’s largest shareholder Meteva AS and Oncoinvent’s largest shareholders, Hadean Ventures and Linc AB, all of whom have entered into voting undertakings to vote in favour of the merger and lock-up commitments for a period of six months following this announcement. The merger is expected to be completed in around mid September and the rights issue is expected to be completed during October 2025.

2025

saltx technoloty 30062025

ECM

SEK 50m

Sweden

Industrials

ABG Sundal Collier acted as financial advisor to SaltX Technology in connection with a capital raise of approx. SEK 50m

On Monday 30 June 2025, SaltX Technology Holding AB (publ) (“SaltX” or the “Company”) announced a strategic partnership with a subsidiary of Holcim. Holcim is becoming a strategic shareholder in the Company through an investment of approximately SEK 38.9m. Furthermore, the Company has secured an investment of approximately SEK 10.0m from Coeli.

SaltX is a Swedish greentech company that develops and markets sustainable technology that will benefit customers, the climate, and society. The company operates within the electrification of emission-intensive industries such as the lime and cement industries.

2025

evelon 30062025

M&A

Undisclosed

Norway

IT

ABG Sundal Collier acted as exclusive financial advisor to the selling shareholders in the sale of Evelon AS to Upheads AS

On 30 June 2025, it was announced that Upheads AS (“Upheads”) has agreed to acquire the majority of the shares in Evelon AS (“Evelon”, the “Company”) for an undisclosed consideration.

Evelon is a Norwegian managed IT service provider with a strong foothold in South-East Norway, established through the merger of four well-performing IT service companies. The Company is a one-stop shop provider of business-critical services to SMEs, delivered as-a-service on a modern IT platform. Evelon reported FY2024 revenues of NOK 188 million.

Upheads is one of Norway’s largest providers of IT services and security for SMEs. In the last 5 years, Upheads has grown from 70 to 370 employees. Upheads emphasises IT security, Microsoft cloud services, and personalised support.